Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Me is teetering on the edge of bankruptcy and actively seeking a buyer. That buyer, unless explicitly restricted, could gain ...

Johannesburg: Testing and monitoring of HIV patients ... Given a summary of the data, Foster Mohale, a spokesperson for South Africa's Department of Health, said more analysis was needed and ...

The CDC has also stopped collecting data regarding trans people, including in HIV surveillance systems, and paused public awareness campaigns about HIV. And the administration has canceled at ...

The second analysis included 381 virologically suppressed women living with HIV. At a median of one year, 94% of participants maintained virologic suppression, and the CVF rate was ≤1.3%. The Trio ...

London, 12 March 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation ... In a ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented ... CROI in two poster sessions. An interim analysis of surveys included 2,561 trial ...

Phase 1 Data Indicate Potential for Use of Once-Yearly Lenacapavir for HIV Prevention, with Plans to Launch a Phase ... were also presented at CROI in two poster sessions. An interim analysis of ...

Since Trump’s inauguration, an NBC News analysis found ... year for which granular data are available, Blacks and Latinos accounted for 37% and 33% of new HIV cases, despite being just 12% ...

Introduction Refugees experience HIV vulnerabilities due to ... access to the dataset for the purpose of data management and outcome reporting, and all datasets will be saved on a password-protected ...